Zoetis Inc. (NYSE: ZTS)
Health Care · Pharmaceuticals · US
$77.52
+0.30% today · -49.9% 1Y
Zoetis Inc. (NYSE: ZTS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $32.03B and employs 14,500 people.
Over the last twelve months the share price has lost 49.9%, trading between 71.00 and 156.49.
Tweenvest scores Zoetis Inc. across four factors: quality 84/100, value 87/100, growth 54/100, dividend 82/100. Its strongest factor is value.
ZTS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $32.03B
- Revenue (TTM)
- $9.53B
- P/E
- 12.65
- EPS
- 6.13
- Dividend yield
- 2.74%
- Beta (5Y)
- 0.73
- 52-week high
- $156.49
- 52-week low
- $71.00
- Avg volume (3M)
- —
- Shares outstanding
- 413.22M
- Employees
- 14,500
- Next earnings
- —
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- ISIN
- US98978V1035
- Founded
- 2012
- Listed since
- Feb 1, 2013
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.06T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $377.72B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $365.10B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $300.07B | CHF127.18 | -0.90% |
| AstraZeneca PLCLSE: AZN | $257.89B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $210.23B | Dkr304.95 | -0.93% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.